JP2020512978A - アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法 - Google Patents

アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法 Download PDF

Info

Publication number
JP2020512978A
JP2020512978A JP2019553167A JP2019553167A JP2020512978A JP 2020512978 A JP2020512978 A JP 2020512978A JP 2019553167 A JP2019553167 A JP 2019553167A JP 2019553167 A JP2019553167 A JP 2019553167A JP 2020512978 A JP2020512978 A JP 2020512978A
Authority
JP
Japan
Prior art keywords
polypeptide
αvβ3
cancer
antibody
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512978A5 (show.php
Inventor
デイビッド チェレッシュ，
デイビッド チェレッシュ，
ヒロミ ウェッターステン，
ヒロミ ウェッターステン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2020512978A publication Critical patent/JP2020512978A/ja
Priority to JP2021054730A priority Critical patent/JP2021095423A/ja
Publication of JP2020512978A5 publication Critical patent/JP2020512978A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019553167A 2017-03-31 2018-03-30 アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法 Pending JP2020512978A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021054730A JP2021095423A (ja) 2017-03-31 2021-03-29 アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762479768P 2017-03-31 2017-03-31
US62/479,768 2017-03-31
PCT/US2018/025470 WO2018183894A1 (en) 2017-03-31 2018-03-30 Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021054730A Division JP2021095423A (ja) 2017-03-31 2021-03-29 アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2020512978A true JP2020512978A (ja) 2020-04-30
JP2020512978A5 JP2020512978A5 (show.php) 2021-05-06

Family

ID=63676868

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019553167A Pending JP2020512978A (ja) 2017-03-31 2018-03-30 アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法
JP2021054730A Pending JP2021095423A (ja) 2017-03-31 2021-03-29 アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021054730A Pending JP2021095423A (ja) 2017-03-31 2021-03-29 アルファ−Ｖ ベータ−３（αｖβ３）陽性がん幹細胞（ＣＳＣＳ）を処置および殺滅するためならびに薬物耐性がんを処置するための組成物および方法

Country Status (12)

Country Link
US (2) US20200109205A1 (show.php)
EP (2) EP4353318A3 (show.php)
JP (2) JP2020512978A (show.php)
KR (1) KR102630070B1 (show.php)
CN (1) CN110662559A (show.php)
AU (1) AU2018243670B2 (show.php)
BR (1) BR112019020451A2 (show.php)
CA (1) CA3058458A1 (show.php)
EA (1) EA201992326A1 (show.php)
IL (1) IL269746A (show.php)
MX (1) MX2019011717A (show.php)
WO (1) WO2018183894A1 (show.php)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12383634B2 (en) 2019-07-24 2025-08-12 Korea Basic Science Institute Single domain antibody targeting αVβ3 integrin
KR20220041111A (ko) * 2019-08-02 2022-03-31 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 알파-v 베타-3-양성 암 줄기 세포 (csc)를 표적화하여 사멸시키고 약물 저항성 및 전이성 암을 치료하기 위한 조성물 및 방법
WO2021216956A1 (en) * 2020-04-23 2021-10-28 Alpha Beta Holdings, Llc Compositions and methods for treating cancer
CN112626118B (zh) * 2020-11-12 2023-06-23 清华-伯克利深圳学院筹备办公室 细胞株及其应用
WO2023056326A1 (en) * 2021-09-30 2023-04-06 Alpha Beta Holdings, Llc Compositions and methods for treating cancer
CN115960160B (zh) * 2021-10-12 2024-07-16 南京大学 活细胞膜整合素αvβ3聚糖的原位糖链延长方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533001A (ja) * 2002-03-04 2005-11-04 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
WO2012167028A2 (en) * 2011-06-02 2012-12-06 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
SK163598A3 (en) * 1996-05-31 1999-06-11 Scripps Research Inst Methods and compositions useful for inhibition of angiogenesis
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
EP1005327A1 (en) 1997-07-02 2000-06-07 Sdg, Inc. Targeted liposomal constructs for diagnostic and therapeutic uses
PL200919B1 (pl) * 1999-02-12 2009-02-27 Lexigen Pharm Corp Zastosowanie kompozycji czynnika hamującego angiogenezę i czynnika przeciwnowotworowego, kompozycja terapeutyczna do leczenia nowotworów i zestaw do traktowania komórki nowotworowej
CN1198590C (zh) 1999-04-23 2005-04-27 三菱化学株式会社 与抗体和聚亚烷基二醇结合的脂质体
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7858117B2 (en) 2002-02-21 2010-12-28 Novosom Ag Amphoteric liposomes and their use
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
KR20060123384A (ko) 2003-12-24 2006-12-01 가부시키가이샤 엘티티 바이오파마 약물을 함유하는 나노 입자 및 그 제조 방법, 그리고 당해나노 입자로 이루어지는 비경구 투여용 제제
WO2005084710A2 (en) 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
WO2006014035A1 (en) 2004-08-06 2006-02-09 Biospectrum, Inc. Multiple layered liposome and preparation method thereof
WO2006023420A2 (en) * 2004-08-16 2006-03-02 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
DK1896071T3 (en) * 2005-06-30 2015-05-26 Janssen Biotech Inc Methods and compositions with increased therapeutic activity
WO2007012191A1 (en) 2005-07-27 2007-02-01 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
US20080088046A1 (en) 2006-10-13 2008-04-17 Steffen Panzner Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
WO2007059195A1 (en) * 2005-11-14 2007-05-24 University Of Southern California Integrin-binding small molecules
US20080089928A1 (en) 2006-06-13 2008-04-17 Stavroula Sofou Liposome drug carriers with ph-sensitivity
US20110319335A1 (en) * 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
CN106232625B (zh) * 2013-10-01 2020-04-24 免疫医疗有限公司 治疗和诊断过表达α-V-β-6的癌症的方法
JPWO2015068847A1 (ja) * 2013-11-11 2017-03-09 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
WO2016100858A1 (en) * 2014-12-18 2016-06-23 The Regents Of The University Of California Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype
KR20220041111A (ko) * 2019-08-02 2022-03-31 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 알파-v 베타-3-양성 암 줄기 세포 (csc)를 표적화하여 사멸시키고 약물 저항성 및 전이성 암을 치료하기 위한 조성물 및 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533001A (ja) * 2002-03-04 2005-11-04 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
WO2012167028A2 (en) * 2011-06-02 2012-12-06 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition

Also Published As

Publication number Publication date
KR20190133205A (ko) 2019-12-02
AU2018243670B2 (en) 2025-05-01
WO2018183894A1 (en) 2018-10-04
KR102630070B1 (ko) 2024-01-26
EP3600422A4 (en) 2021-01-13
US20200109205A1 (en) 2020-04-09
EP4353318A2 (en) 2024-04-17
EP4353318A3 (en) 2024-07-17
AU2018243670A1 (en) 2019-10-31
JP2021095423A (ja) 2021-06-24
US20240067733A1 (en) 2024-02-29
BR112019020451A2 (pt) 2020-04-28
EA201992326A1 (ru) 2020-03-13
EP3600422A1 (en) 2020-02-05
MX2019011717A (es) 2019-12-16
EP3600422B1 (en) 2023-10-18
CN110662559A (zh) 2020-01-07
IL269746A (en) 2019-11-28
CA3058458A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
US20240067733A1 (en) Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers
US20210077510A1 (en) Compositions and methods for inhibiting arginase activity
JP6865177B2 (ja) 医薬組み合わせおよびその使用
JP2014132009A5 (show.php)
CN120285177A (zh) Hdac抑制剂和pd-1抑制剂的组合疗法
JP2012500180A5 (show.php)
WO2018223923A1 (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
JP7703513B2 (ja) 抗ガレクチン９抗体と化学療法剤の組合せがん治療
EP3638228A1 (en) Compounds for treating tnbc
US11052089B2 (en) Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype
KR20230098279A (ko) Pdx 억제제 또는 독소루비신과 ahr 억제제의 조합
US20210267972A1 (en) Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies
CN117015377A (zh) 使用波生坦与检查点抑制剂组合的癌症治疗
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
CN114144181A (zh) 用于靶向和杀死α-vβ-3（αvβ3）阳性癌症干细胞（CSC）以及治疗耐药性和转移性癌症的组合物和方法
US20220233531A1 (en) Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
HK40110133A (en) Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers
CN117677398A (zh) 用于癌的治疗和/或预防的药品
BR122024020789A2 (pt) Composições e métodos para se direcionar e matar células-tronco positivas de câncer alfa-v beta-3 positiva (cscs) e tratamento de cânceres resistentes ao medicamento
RU2830077C2 (ru) Введение ингибитора sumo-активирующего фермента и ингибиторов контрольных точек
WO2024047196A1 (en) Use of an agent capable of inhibiting the activation of mait cells for the treatment of rheumatoid arthritis
WO2023073645A1 (en) Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
CN119546293A (zh) Hdac抑制剂和他汀类药物的组合用于治疗胰腺癌
CN117693363A (zh) 用于癌的治疗和/或预防的药品
HK40069657B (zh) 抗半乳糖凝集素-9 抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221028